FDA IND follows promising Phase 2 results presented at 2024 ASCO GI revealing that the addition of HLX22 (AC101) to biosimilar trastuzumab a ...

Next-generation CD40 agonists have opportunity to address key biological and medical needs in immuno-oncology Bispecific CD40-targeting anti ...

Study conducted by Moores Cancer Center at University of California San Diego to evaluate safety and efficacy of mitazalimab injected intrat ...